We are excited to announce that WuXi subsidiary STA Pharmaceutical Co., Ltd. (STA)  has merged with our Pharmaceutical Development Services (PDS) division. The PDS division offers pre-formulation development, formulation development, as well as Clinical Trial Material (CTM) manufacturing, packaging and labeling of oral solid dosage forms including tablets, capsules, sachets and oral solutions/suspensions.

STA Pharmaceutical, after this merger, will provide fully integrated small molecule Active Pharmaceutical Ingredient (API) and drug product solutions to global clients, resulting in a seamless Chemistry, Manufacturing and Control  (CMC) working process. The merger enables STA to advance New Chemical Entities from pre-clinical stage to New Drug Application (NDA) and to market faster and more efficiently for pharma and biotech customers.

The merging of the PDS division into STA is an important step for WuXi. Providing API and drug product services under one STA entity further strengthens WuXi’s comprehensive CDMO offering. Ultimately, our platforms advance vital new medicines through the development cycle faster, allowing our global partners to discover and develop better medicines for patients.

Related Links:

WuXi’s Pharmaceutical Development Services Division Merges with STA

WuXi PharmaTech and Lilly Announce Strategic Collaboration to Develop Novel Therapeutic in China